Navigation Links
BioLineRx Ltd. Retains KCSA Strategic Communications as U.S. Investor Relations Counsel

JERUSALEM, Sept. 22, 2011 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to direct the Company's investor relations program.

KCSA intends to deploy a comprehensive investor relations communication campaign designed to increase awareness of BioLineRx among the U.S. investment community. Since KCSA's inception over forty years ago, the firm has developed a strong reputation for its work representing both domestic and international public companies. Todd Fromer, Managing Partner of KCSA, will lead the KCSA team and provide strategic counsel on financial communication matters.

"I am excited to begin working with KCSA in order to create greater awareness of BioLineRx in the U.S. investment community. We have several exciting products in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities to grow our business. With KCSA's proactive communications program, we hope to highlight the ongoing development of these products to our shareholders and potential value of these products upon receiving regulatory market clearance," said Dr. Kinneret Savitsky, BioLineRx's Chief Executive Officer.

Mr. Fromer stated, "Since listing its ADRs on the NASDAQ in July, BioLineRx has had little exposure to the U.S. investment community.  As such, we believe there is a tremendous opportunity for us to broaden awareness among investors and highlight the opportunity BioLineRx and its products provide. As part of our program, we will work with the BioLineRx management team to effectively and regularly communicate with its U.S. investor base."

In July 2011, BioLineRx listed its shares on the NASDAQ Capital Market, through ADRs. Each BioLineRx ADR represents 10 ordinary shares and trades on NASDAQ under the symbol "BLRX."

About BioLineRx

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia is in Phase II/III clinical trials; BL-1040 for treatment of patients following a myocardial infarction has completed a Phase I/II study and has been out-licensed to Ikaria Inc. for a total deal value of $282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in the final stages of a Phase I trial; and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has nine products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit

About KCSA Strategic Communications

KCSA is a fully integrated communications agency specializing in public relations, investor relations and marketing with expertise in financial and professional services, technology, healthcare, media, energy and public services companies. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit

Investor Contacts:

KCSA Strategic Communications
Todd Fromer / Garth Russell
+ 212-682-6300 /

SOURCE KCSA Strategic Communications; BioLineRx Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Retains Hayden IR to Develop Comprehensive Investor Relations Program
2. Access Pharmaceuticals Retains Edelman as Public Relations Firm
3. American Scientific Resources Retains National PR/IR Firm
4. XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System
5. Access Pharmaceuticals Retains eMAX Health to Expand MuGard Distribution Network and Supplement Payer Outreach Programs
6. BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent
7. AmbiCom Retains Hayden IR to Develop Strategic Investor Relations Program
8. NeuroSigma, Inc. Retains CCG Investor Relations
9. BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
10. Dehaier Medical Retains The Piacente Group as Strategic Investor Relations Consulting Firm
11. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... According to an article published November 13th on, ... D.C. revolved around the fact that proper dental care, both at-home and in the ... between periodontal disease (more commonly referred to as gum disease) and diabetes. According to ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of ... in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately ... nationally, through a vast social media strategy and across a network of top ...
(Date:11/27/2015)... ... 27, 2015 , ... Intellitec Solutions announced today that they ... Recognized as Microsoft’s official group for end users of Dynamics SL ERP software, ... industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):